ResMed Q1 FY27: EPS jumps 23% to $2.92 on MatrixCare sale; $450M ASR buyback

Filed October 30, 2026 · Period ending September 30, 2026 · Compared to 10-Q Oct 31, 2025 · ~1 min read

Key Changes

• high

  Net income rose 20.0% to $418.4M, and diluted EPS jumped 23.2% to $2.92, boosted by a $62M gain on the MatrixCare divestiture.

  MD&A: Results verify on EDGAR →
• high

  ResMed completed the sale of MatrixCare on Sept 1, 2026, receiving $470M net cash proceeds and recording a $62M pre-tax gain.

  Notes: Divestiture verify on EDGAR →
• high

  The company entered a $450M accelerated share repurchase agreement, receiving 1.6M shares initially; total Q1 buybacks were $855M vs $150M a year ago.

  MD&A: Capital Allocation verify on EDGAR →